Updated data will be presented.Conclusions:OTX-2002 is well-tolerated and induces rapid and durable epigenomic changes to the MYC locus. These results provide clinical proof of mechanism of the epigenomic controller platform and support continued development of OTX-2002.Clinical trial information: NCT...
Phase 1/2 Clinical Trial Expected to Launch in 2H'22 and Will Evaluate the Safety and Preliminary Antitumor Activity of OTX-2002 CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ -- Omega Therapeutics Inc. (Nasdaq: OMG...
OTX-2002 is currently under clinical evaluation in the Phase 1/2 MYCHELANGELO™ I trial in adult patients with HCC and other MYC-associated solid tumors (NCT05497453). About the OMEGA platform The OMEGA platform leverages the Company’s deep understanding of gene regulation, genomic architecture ...
MYCHELANGELO I (NCT05497453) is a Phase 1/2 open label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OTX-2002 as a monotherapy (Part 1) and in combination with...
trial, which is currently being conducted at clinical sites across the United States and Asia. Patients were treated intravenously with either 0.02 mg/kg (n=4) or 0.05 mg/kg (n=4) of OTX-2002 once every two weeks. Changes in MYC DNA methylation and m...
The Company plans to initiate a Phase 1 clinical trial in the U.S. to evaluate OTX-2002, following FDA clearance. About OTX-2002 OTX-2002 is a first-in-class Omega Epigenomic Controller™ in develop...